Zentalis Pharmaceuticals (NASDAQ:ZNTL) Announces Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) posted its earnings results on Thursday. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.08), FiscalAI reports.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL traded up $0.12 during trading hours on Thursday, reaching $2.67. 428,202 shares of the company’s stock were exchanged, compared to its average volume of 1,321,288. The company has a market capitalization of $192.91 million, a price-to-earnings ratio of -1.29 and a beta of 1.71. The company’s 50-day moving average is $2.59 and its two-hundred day moving average is $1.93. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95.

Insider Buying and Selling

In other news, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider owned 156,779 shares in the company, valued at $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Group Walters acquired 6,459,973 shares of the stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the transaction, the insider directly owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders sold 46,617 shares of company stock worth $113,417. Insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC lifted its stake in Zentalis Pharmaceuticals by 60.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock valued at $108,000 after acquiring an additional 30,000 shares during the last quarter. Opal Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $98,000. Squarepoint Ops LLC increased its stake in shares of Zentalis Pharmaceuticals by 405.3% during the 4th quarter. Squarepoint Ops LLC now owns 107,734 shares of the company’s stock worth $145,000 after purchasing an additional 86,412 shares during the last quarter. Quarry LP raised its holdings in shares of Zentalis Pharmaceuticals by 21.4% in the 4th quarter. Quarry LP now owns 132,000 shares of the company’s stock valued at $178,000 after purchasing an additional 23,250 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in Zentalis Pharmaceuticals by 145.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 173,484 shares of the company’s stock valued at $201,000 after purchasing an additional 102,661 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company assumed coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $5.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.